Adam Crystal - 02 Feb 2026 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Role: President, R&D
Signature: /s/ Daniella Beckman, as attorney-in-fact
Issuer symbol: TNGX
Transactions as of: 02 Feb 2026
Net transactions value: -$226,300
Form type: 4
Filing time: 04 Feb 2026, 20:02:17 UTC
Previous filing: 06 Feb 2025
Next filing: 27 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Crystal Adam	President, R&D	C/O TANGO THERAPEUTICS, INC.,, 201 BROOKLINE AVE., SUITE 901, BOSTON	/s/ Daniella Beckman, as attorney-in-fact	04 Feb 2026	0001825445

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TNGX	Common Stock	Award	$0	+47,460	+30%	$0.000000	205,670	02 Feb 2026	Direct	F1
transaction	TNGX	Common Stock	Sale	$223,708	-18,251	-8.9%	$12.26	187,419	03 Feb 2026	Direct	F2, F3
transaction	TNGX	Common Stock	Sale	$2,592	-201	-0.11%	$12.90	187,218	03 Feb 2026	Direct	F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TNGX	Stock Option (Right to Buy)	Award	$0	+284,760		$0.000000	284,760	02 Feb 2026	Common Stock	284,760	$11.94	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2	The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
F3	Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4	Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F5	This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2027 with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.